Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

Lilly yesterday announced the next component in the ‘beyond the pill’ strategy it is constructing for diabetes, a new alliance with digital health company Rimidi.

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The Fund performed roughly in line with the Benchmark, during a challenging ...

Those at risk include people living with type 2 diabetes or high blood pr Eli Lilly and Company (NYSE: LLY) today announced a $3 billion expansion of the Kenosha County, Wisconsin, manufacturing ...

It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy ...

Background: Failure to detect significant drug interactions may result in adverse outcomes. While proper screening and management of drug interactions can prevent the majority of adverse events ...

Am J Health Syst Pharm. 2006;63(8):712-714. Drug information specialists are pharmacists whose primary responsibility is the provision of drug information. As with any specialty, formalized ...

Marika Carlton, Jorja Davey and Ella Ward were among the visitors best while Waratah’s Brittany Daly, Jamilla Cranny and Lilly Rydon earned best players nominations. Nightcliff Tigers' Georgia ...

Treating older people with diabetes is challenging due to multiple medical comorbidities that might interfere with patients' ...